CRSF & Leading Pharma Cos Unveils Lung Next Gen Sequencing Biomarker Tests in India
Supported by leading pharmaceutical companies AstraZeneca, Pfizer, and Roche, the initiative has 4baseCare as its official lab partner.
LuNGS Alliance, an initiative led by the Cancer Research and Statistic Foundation (CRSF), has launched a free Lung NGS (Next Generation Sequencing) biomarker testing program for lung cancer patients across India.
Supported by leading pharmaceutical companies AstraZeneca, Pfizer, and Roche, the initiative has 4baseCare as its official lab partner.
The TARGT First Solid test by 4baseCare conducts an extensive analysis of 72 commonly mutated genes, identifying actionable biomarkers that enable personalized treatment plans tailored to each patient’s unique genomic profile.
This advanced test detects mutations linked to FDA and NCCN-approved therapies, allowing oncologists to deliver highly targeted and effective treatments that significantly enhance patient outcomes.
By offering free biomarker testing, LuNGS Alliance aims to make cutting-edge cancer care more accessible and ensure that financial limitations do not prevent patients from accessing the most advanced treatment options.
A study published in The Lancet Regional Health estimates that lung cancer accounts for 72,510 new cases and 66,279 deaths annually in India.
Therefore, the high mortality rate highlights the urgent need for personalized treatment approaches over conventional methods. Biomarker testing provides a solution by enabling targeted therapies tailored to a patient's genetic mutations.
Lung cancer patients can receive one complimentary NGS biomarker test through this initiative.
